JSJonathan E. Shaw

Jonathan E. Shaw

*This is an algorithmically generated author record based on publicly available information.

Jonathan E. Shaw has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Changes in the rates of weight and waist circumference gain in Australian adults over time

    by Anna Peeters, Dianna J. Magliano, Kathryn Backholer, Paul Zimmet, Jonathan Shaw

  • Sleep-disordered breathing and type 2 diabetes

    by Jonathan E. Shaw, Naresh M. Punjabi, John P. Wilding, K. George M.M. Alberti, Paul Z. Zimmet


  • Epidemiology of childhood type 2 diabetes and obesity

    by Jonathan Shaw

    Over the last decade, it has become apparent that type 2 diabetes extends not only into the young adult population but is also found in adolescents and even, occasionally, in children. The limited data that are currently available present a rather uncertain picture, with a rather wide range of prevalences and incidences of type 2 diabetes in children and adolescents. Not surprisingly, the majority of the cases, and the highest prevalences, have been found among ethnic groups known to be at high risk of adult type 2 diabetes. Nevertheless, even in European populations, where the prevalence of type 2 diabetes remains very low among children and adolescents and certainly is considerably smaller than type 1 diabetes, there are several cases reported. The risk factors for type 2 diabetes in children and adolescents are, as expected, similar to those seen in adults, with obesity being almost always present. In utero exposure to hyperglycemia now appears to be an additional risk factor to having a family history of diabetes and suggests that better management of diabetes in pregnancy and prevention of gestational diabetes may reduce the risk of diabetes developing in the offspring.


  • Open Access

    Point: Impaired Fasting Glucose: The Case for the New American Diabetes Association Criterion

    by Jonathan E. Shaw, Paul Z. Zimmet, K. George M.M. Alberti

    In 1979 and 1980, both the National Diabetes Data Group (1) and the World Health Organization (WHO) (2) formally defined a postchallenge state of glucose tolerance that lay between what was considered normal and diabetic. This state was defined as an elevated 2-h plasma glucose with a nondiabetic fasting glucose level and was termed “impaired glucose tolerance” (IGT). Those individuals falling within the new IGT range were known to have an increased risk of future diabetes and of cardiovascular disease (CVD). It took almost another 20 years to officially recognize that a similar category existed for elevated, but nondiabetic, fasting glucose levels. In 1997 and 1999, the American Diabetes Association (ADA) and the WHO, respectively, added the term “impaired fasting glucose” (IFG) (with the WHO using “impaired fasting glycemia”) to the available diagnostic categories (3,4). It was defined as a fasting plasma glucose (FPG) of 110–125 mg/dl (6.1–6.9 mmol/l). While it was clear that FPG values below the diabetes threshold were predictive of future diabetes and CVD, it was less obvious where the appropriate cut point between normal and IFG status should lie. The report of the ADA’s 1997 Expert Committee on the Diagnosis and Classification of Diabetes (3) cites several earlier studies on which the cut point of 110 mg/dl (6.1 mmol/l) was based. The first is, in fact, the origin of both the name, IFG, and the cut point (5). In an analysis of the Paris Prospective Study, Charles et al. (5) selected a group of people just below the then fasting diabetes threshold of 140 mg/dl (7.8 mmol/l) from the cohort to determine whether elevated, nondiabetic fasting glucose levels were comparable to IGT in predicting incident diabetes. To make the comparison with IGT even handed, they chose a fasting glucose cut point that would include …


  • Open Access

    Study Protocol – Diabetes and related conditions in urban Indigenous people in the Darwin, Australia region: aims, methods and participation in the DRUID Study

    by Joan Cunningham, Kerin O'Dea, Terry Dunbar, Tarun Weeramanthri, Paul Zimmet, Jonathan Shaw

    Background Diabetes mellitus is a serious and increasing health problem in Australia and is a designated national health priority. Diabetes and related conditions represent an even greater health burden among Indigenous Australians (Aborigines and Torres Strait Islanders), but there are critical gaps in knowledge relating to the incidence and prevalence, aetiology, and prevention of diabetes in this group, including a lack of information on the burden of disease among Indigenous people in urban areas. The DRUID Study (Diabetes and Related conditions in Urban Indigenous people in the Darwin region) was designed to address this knowledge gap. Methods/design The study was conducted in a specified geographic area in and around Darwin, Australia. Eligible participants underwent a health examination, including collection of blood and urine samples, clinical and anthropometric measurements, and administration of questionnaires, with an additional assessment for people with diabetes. The study was designed to incorporate local Indigenous leadership, facilitate community engagement, and provide employment and training opportunities for local Indigenous people. A variety of recruitment methods were used. A total of 1,004 eligible people gave consent and provided at least one measurement. When compared with census data for the Indigenous population living in the study area, there was a marked under-representation of males, but no substantial differences in age, place of residence, Indigenous group, or household income. Early participants were more likely than later participants to have previously diagnosed diabetes. Discussion Despite lower than anticipated recruitment, this is, to our knowledge, the largest study ever conducted on the health of Indigenous Australians living in urban areas, a group which comprises the majority of Australia's Indigenous population but about whose health and wellbeing relatively little is known. The study is well-placed to provide new information that can be used by policy makers and service providers to improve the delivery of services and programs that affect the health of Indigenous people. It also represents a valuable opportunity to establish an urban Indigenous cohort study, provided participants can be followed successfully over time.


  • Impact of new diagnostic criteria for diabetes on different populations.

    by J E Shaw, M de Courten, E J Boyko, P Z Zimmet

    OBJECTIVE: For epidemiological purposes, it has now been recommended that a fasting plasma glucose value of 7.0 mmol/l can be used to diagnose diabetes, instead of a 2-h value of 11.1 mmol/l. This study assesses the impact of making this change on the prevalence of diabetes and on the phenotype of individuals identified. RESEARCH DESIGN AND METHODS: Data were collated from nine population based southern hemisphere studies in which a 75-g oral glucose tolerance test was performed. Comparisons were made between the prevalence derived from fasting values only and the prevalence derived from 2-h values only. Cardiovascular risk was assessed in all individuals. RESULTS: There were 20,624 subjects in the nine surveys of whom 1,036 had previously diagnosed diabetes and 1,714 had newly diagnosed diabetes, according to either fasting or 2-h glucose. The differences in prevalence within each population resulting from changing the diagnostic criteria ranged from +30 to -19% (relative difference) and +4.1 percentage points to -2.8 percentage points (absolute difference). BMI was the most important determinant of disagreement in classification. A total of 31% of those individuals who were diabetic on the fasting value were not diabetic on the 2-h value, and 32% of those with diabetes on the 2-h value were not diabetic on the fasting value. Apart from obesity, there were no differences in cardiovascular risk between those identified by the fasting and the 2-h values. CONCLUSIONS: Changing the diagnostic criteria is likely to have variable and sometimes quite large effects on the prevalence of diabetes in different populations. Furthermore, the fasting criterion identifies different people as being diabetic than those identified by the 2-h criterion.


  • Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius?

    by J E Shaw, P Z Zimmet, M de Courten, G K Dowse, P Chitson, H Gareeboo, F Hemraj, D Fareed, J Tuomilehto, K G Alberti

    OBJECTIVE: To determine if impaired fasting glucose (IFG; fasting plasma glucose level 6.1-6.9 mmol/l) can predict future type 2 diabetes as accurately as does impaired glucose tolerance (IGT; 2-h plasma glucose level 7.8-11.0 mmol/l). RESEARCH DESIGN AND METHODS: A longitudinal population-based study was performed with surveys in 1987 and 1992 on the island of Mauritius, assessing diabetes status by the oral glucose tolerance test. A total of 3,717 subjects took part in both surveys. Of these subjects, 3,229 were not diabetic in 1987 and formed the basis of this study. RESULTS: At baseline, there were 607 subjects with IGT and 266 subjects with IFG. There were 297 subjects who developed diabetes by 1992. For predicting progression to type 2 diabetes, the sensitivity, specificity, and positive predictive values were 26, 94, and 29% for IFG and 50, 84, and 24% for IGT, respectively. Only 26% of subjects that progressed to type 2 diabetes were predicted by their IFG values, but a further 35% could be identified by also considering IGT. The sensitivities were 24% for IFG and 37% for IGT in men and 26% for IFG and 66% for IGT in women, respectively. CONCLUSIONS: These data demonstrate the higher sensitivity of IGT over IFG for predicting progression to type 2 diabetes. Screening by the criteria for IFG alone would identify fewer people who subsequently progress to type 2 diabetes than would the oral glucose tolerance test.


  • An analysis of dynamic forces transmitted through the foot in diabetic neuropathy.

    by J E Shaw, C H van Schie, A L Carrington, C A Abbott, A J Boulton

    OBJECTIVE: Biomechanical studies in diabetic neuropathy have clearly demonstrated abnormal foot pressures, but information on other aspects of gait is limited. This study aimed to investigate and describe the forces transmitted through the foot during walking in diabetic subjects with varying degrees of peripheral neuropathy and to determine if abnormalities in these forces might contribute to the risk of plantar ulceration. RESEARCH DESIGN AND METHODS: Subjects from the following groups were included: healthy control subjects (C); diabetic control subjects (D); subjects with diabetic neuropathy (DN); subjects with previous neuropathic ulceration (DNU); and subjects with Charcot neuro-arthropathy (CH). Gait analysis was performed as subjects walked over a Kistler force plate. Peak forces were measured (as percent body weight) in the vertical and horizontal planes. Comparisons were made between all of the groups and between each diabetic group and a healthy control group matched for walking speed. RESULTS: There were 181 subjects studied. In comparison with that of the speed-matched controls, the mean peak vertical force was higher in each of the diabetic groups, especially in the most neuropathic subjects (DNU, 113 vs. 110%, P < 0.01). This increase was entirely due to higher forces during heel contact (DNU, 111 vs. 106%, P < 0.001). The single peak force occurred during heel strike (rather than during foot push-off) in 23-38% of footsteps of healthy and diabetic control subjects but in 53-73% of footsteps of neuropathic subjects. There was also a trend for higher peak medial forces (CH, 6.2 vs. 5.5%, P < 0.05). CONCLUSIONS: Diabetic neuropathy is associated with a change in the time pattern of the forces transmitted through the foot and an increase in the vertical forces through the heel. The magnitude of the changes is small in absolute terms, but these changes may contribute to the risk of plantar foot ulceration.


  • Diabetic neuropathy in Mauritius: prevalence and risk factors

    by Jonathan E Shaw, Allison M Hodge, Maximilian de Courten, Gary K Dowse, Hassam Gareeboo, Jaakko Tuomilehto, K.GEorge M.M Alberti, Paul Z Zimmet